About us

Acesis BioMed is a Colorado (US) & London (UK) based biomedical company operating through Acesis Holdings Corporation and its subsidiaries – Acesis Biomed US, Inc. and Acesis Biomed Ltd - developing a platform of oral drug candidates for metabolic and endocrine disorders, initially focusing on male hypogonadism treatment (low T) and related co-morbidities.

  • Hypogonadism indication provides Acesis with a target market of ~$3 Billion
  • Co-morbidities of low T such as obesity, fatty liver disease, prediabetes, cachexia (in cancer, HIV) offer additional target addressable markets
  • The company’s proprietary “first-in-class” T peptide modulator designed as a safer solution to the existing Testosterone Replacement Therapy (TRT)*
  • Upon regulatory approval, we envision our drug candidate to become a transformative solution for the treatment of male hypogonadism globally

* based on our preclinical data; to be tested extensively in clinical trials

About

Key Achievements

Key

Transformative Innovation

  • Dr. Papadopoulos, discovered a novel steroid biosynthesis mechanism, revealing key regulators of mitochondrial cholesterol transport—an essential step in testosterone production and a target for new drug design. This discovery led to two families of patents owned by Acesis.
  • $12 million in research grants awarded in the lab of Dr Papadopoulos (US and Canada).
Key

Operations

  • Acesis has secured $5.8M in funding (since 2015).
  • Operating as a virtual organization, Acesis avoids capital-intensive labs and infrastructure; execution of Research & Development by partnering with Academic centers and contract research organizations (CROs).
Key

Developmental Path

  • Process for multigram-scale drug production achieved to support preclinical and future clinical programs.
  • Aggressive roadmap and partnerships with CROs ensure a seamless path to finalizing preclinical work towards First in Man clinical trials.
Key

Expert Leadership

  • Management, Board of Directors and Scientific Advisory Board have diverse expertise in start-ups, operations, financing, fundraising, drug development, clinical affairs (urology and endocrinology), intellectual property, and business strategy.
  • We plan to expand our management team based on achieving milestones; we engage consultants in drug development, pharmaceutics, regulatory affairs, and clinical expertise to optimize our strategic direction and plan execution.
Key

Focused Development Approach

  • Our current goal is to complete our preclinical program and transition to First in Man clinical trial in men with low testosterone (male hypogonadism). This is the only FDA-approved indication for current T treatments.
  • We plan to expand our drug pipeline to address a broader range of diseases such as type 2 diabetes, non-alcoholic fatty liver disease, obesity, and cachexia (muscle wasting in cancer and HIV patients) in collaboration with Academia and Pharma.

Dive Into Our Programs

read about our Programs >
Vassilios Papadopoulos